CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Just a reminder that the revised client forms implement today! Don't forget to toss your o...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...
The new Learning Center website launch today on Monday, March 30, 2020. While the link to the new Le...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...